Fospropofol disodium

Fospropofol disodium is a water-soluble prodrug of propofol, a commonly used intravenous anesthetic. It was developed to provide a safer and more manageable alternative to propofol, which has a narrow therapeutic index and can cause significant pain upon injection.

History

Fospropofol disodium was developed by MGI Pharma, a biopharmaceutical company based in the United States. It was approved by the Food and Drug Administration (FDA) in December 2008 for use as a sedative in adults undergoing diagnostic or therapeutic procedures.

Pharmacology

Fospropofol disodium is metabolized in the body to release propofol, phosphate, and formaldehyde. The formaldehyde is further metabolized to formate, which is eliminated in the urine. The propofol provides the sedative effects, while the phosphate and formate are considered inactive metabolites.

Clinical Use

Fospropofol disodium is used as a sedative for adults undergoing diagnostic or therapeutic procedures. It is administered intravenously and has a rapid onset of action. The duration of sedation can be controlled by adjusting the dose.

Side Effects

Common side effects of fospropofol disodium include drowsiness, dizziness, and nausea. Serious side effects can include respiratory depression and hypotension. Due to these risks, fospropofol disodium should only be administered by healthcare professionals trained in the administration of general anesthesia.

See Also

• Propofol
• Prodrug
• Anesthetic